<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03738878</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#170762</org_study_id>
    <nct_id>NCT03738878</nct_id>
  </id_info>
  <brief_title>Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1</brief_title>
  <official_title>Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that combined angiotensin receptor&#xD;
      blockade (ARB)/neprilysin (NEP) inhibition potentiates the effects of exogenous bradykinin,&#xD;
      substance P, and brain natriuretic peptide (BNP) on forearm blood flow or endothelial&#xD;
      tissue-type plasminogen activator (t-PA) release compared to ARB alone. A secondary goal is&#xD;
      to determine if there is an interactive effect of ARB/NEP inhibition and dipeptidyl peptidase&#xD;
      4 (DPP4) inhibition on responses to these peptides.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After informed consent is obtained, subjects will undergo a screening history and physical&#xD;
      exam, and anti-hypertensive medications will be withdrawn. During this period, blood pressure&#xD;
      (BP) will be measured every one to three days.&#xD;
&#xD;
      After subjects have been off anti-hypertensive medications for three weeks (four for&#xD;
      spironolactone), they will be randomized to four-week treatment with valsartan 160 mg bid (80&#xD;
      mg bid for one week, then 160 mg bid) or LCZ696 200 bid (100 mg bid for one week, then 200 mg&#xD;
      bid) in a double-blind fashion. On the morning of the 28th day of study drug, subjects will&#xD;
      report to the Vanderbilt Clinical Research Center (CRC) after an overnight fast. Subjects&#xD;
      will be studied in the supine position in a temperature-controlled room. They will be&#xD;
      instrumented for intra-arterial infusions. Subjects will be given their last dose of study&#xD;
      drug. One hour after drug administration, we will measure forearm blood flow (FBF) and give&#xD;
      bradykinin, substance P, or BNP. Each peptide will be infused in three graded doses for five&#xD;
      minutes. After administration of all three peptides, subjects will be allowed to rest for an&#xD;
      hour. Then they will be given a single oral dose of sitagliptin 200 mg and be allowed to rest&#xD;
      for 90 minutes. We will repeat baseline measurements and the peptide infusions with an&#xD;
      intervening rest period. The four-week study treatment and protocol will be repeated after a&#xD;
      three-week washout, until participants complete both arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 15, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>forearm blood flow</measure>
    <time_frame>After four-week treatment with each crossover drug</time_frame>
    <description>Forearm blood flow measured by strain gauge plethysmography before and after intra-arterial peptide infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tissue-type plasminogen activator release</measure>
    <time_frame>After four-week treatment with each crossover drug</time_frame>
    <description>Net release of t-PA across the forearm will be measured before and after intra-arterial infusion of bradykinin and substance P</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>norepinephrine release</measure>
    <time_frame>After four-week treatment with each crossover drug</time_frame>
    <description>Net release of norepinephrine across the forearm will be measured before and after intra-arterial infusion of each peptide</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>valsartan then LCZ696</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After four-week treatment with valsartan, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.&#xD;
Then, after three-week washout and four week therapy with LCZ696, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCZ696 then valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After four-week treatment with LCZ696, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.&#xD;
Then, after three-week washout and four week therapy with valsartan, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>oral valsartan</description>
    <arm_group_label>LCZ696 then valsartan</arm_group_label>
    <arm_group_label>valsartan then LCZ696</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <description>oral LCZ696</description>
    <arm_group_label>LCZ696 then valsartan</arm_group_label>
    <arm_group_label>valsartan then LCZ696</arm_group_label>
    <other_name>Entresto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bradykinin</intervention_name>
    <description>Intra-arterial bradykinin at three graded doses</description>
    <arm_group_label>LCZ696 then valsartan</arm_group_label>
    <arm_group_label>valsartan then LCZ696</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Substance P</intervention_name>
    <description>Intra-arterial substance P at three graded doses</description>
    <arm_group_label>LCZ696 then valsartan</arm_group_label>
    <arm_group_label>valsartan then LCZ696</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BNP</intervention_name>
    <description>Intra-arterial BNP at three graded doses</description>
    <arm_group_label>LCZ696 then valsartan</arm_group_label>
    <arm_group_label>valsartan then LCZ696</arm_group_label>
    <other_name>Nesiritide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>oral sitagliptin</description>
    <arm_group_label>LCZ696 then valsartan</arm_group_label>
    <arm_group_label>valsartan then LCZ696</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with essential hypertension defined as having&#xD;
&#xD;
               1. untreated, seated systolic blood pressure (SBP) of 130 mmHg or greater on three&#xD;
                  separate occasions, or&#xD;
&#xD;
               2. untreated, seated diastolic BP (DBP) of 80 or greater on three separate&#xD;
                  occasions, or&#xD;
&#xD;
               3. taken anti-hypertensive agent(s) for a minimum of six months.&#xD;
&#xD;
          2. For female subjects, the following conditions must be met:&#xD;
&#xD;
               1. postmenopausal status for at least one year, or&#xD;
&#xD;
               2. status post-surgical sterilization, or&#xD;
&#xD;
               3. if of childbearing potential, utilization of adequate birth control and&#xD;
                  willingness to undergo urine beta-human chorionic gonadotropin (hCG) testing&#xD;
                  prior to drug treatment and on every study day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of secondary form of hypertension&#xD;
&#xD;
          2. Symptomatic hypertension and/or SBP&gt;170 mmHg or DBP&gt;110 mmHg, relevant to the washout&#xD;
             period&#xD;
&#xD;
          3. History of hypersensitivity or allergy to any of the study drugs, drugs of similar&#xD;
             chemical classes, angiotensin-converting enzyme inhibitor (ACEi), ARBs, or NEPi, as&#xD;
             well as known or suspected contraindications to the study drugs&#xD;
&#xD;
          4. History of angioedema&#xD;
&#xD;
          5. History of pancreatitis or known pancreatic lesions&#xD;
&#xD;
          6. History of significant cardiovascular disease (other than essential hypertension and&#xD;
             left ventricular hypertrophy)&#xD;
&#xD;
          7. Symptomatic hypotension and/or a SBP&lt;100 mmHg at screening or &lt;95 mmHg during the&#xD;
             study&#xD;
&#xD;
          8. Serum potassium &gt;5.2 mmol/L at screening or &gt;5.4 mmol/L during the study&#xD;
&#xD;
          9. Individuals using oral contraceptives and smokers in order to reduce the risk of&#xD;
             thrombosis following arterial line placement&#xD;
&#xD;
         10. History of serious neurologic disease such as cerebral hemorrhage, stroke, seizure, or&#xD;
             transient ischemic attack within six months&#xD;
&#xD;
         11. Presence of significant pulmonary disorders&#xD;
&#xD;
         12. Type 1 diabetes&#xD;
&#xD;
         13. Poorly controlled type 2 diabetes mellitus (T2DM), defined as a HgbA1c &gt;9%&#xD;
&#xD;
         14. Hematocrit &lt;35%&#xD;
&#xD;
         15. Impaired renal function [estimated glomerular filtration rate (eGFR) of &lt;30&#xD;
             mL/min/1.73 m2] as determined by the four-variable Modification of Diet in Renal&#xD;
             Disease (MDRD) equation, where serum creatinine (Scr) is expressed in mg/dL and age in&#xD;
             years: eGFR (mL/min/1.73m2)=175 • Scr-1.154 • age-0.203 • (1.212 if Black) • (0.742 if&#xD;
             female)&#xD;
&#xD;
         16. Use of hormone-replacement therapy&#xD;
&#xD;
         17. Breast feeding and pregnancy&#xD;
&#xD;
         18. History or presence of immunological or hematological disorders&#xD;
&#xD;
         19. History of malignancy other than non-melanoma skin cancer&#xD;
&#xD;
         20. Diagnosis of asthma requiring use of inhaled beta agonist more than once a week&#xD;
&#xD;
         21. Clinically significant gastrointestinal impairment that could interfere with drug&#xD;
             absorption&#xD;
&#xD;
         22. Impaired hepatic function [aspartate amino transaminase (AST) and/or alanine amino&#xD;
             transaminase (ALT) &gt;3.0 x upper limit of normal range]&#xD;
&#xD;
         23. Any underlying or acute disease requiring regular medication which could possibly pose&#xD;
             a threat to the subject or make implementation of the protocol or interpretation of&#xD;
             the study results difficult, such as arthritis treated with non-steroidal&#xD;
             anti-inflammatory drugs&#xD;
&#xD;
         24. Treatment with chronic systemic glucocorticoid therapy within the last year&#xD;
&#xD;
         25. Treatment with lithium salts&#xD;
&#xD;
         26. History of alcohol or drug abuse&#xD;
&#xD;
         27. Treatment with any investigational drug in the one month preceding the study&#xD;
&#xD;
         28. Mental conditions rendering the subject unable to understand the nature, scope, and&#xD;
             possible consequences of the study&#xD;
&#xD;
         29. Inability to comply with the protocol, e.g., uncooperative attitude, inability to&#xD;
             return for follow-up visits, and unlikelihood of completing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>April 25, 2021</last_update_submitted>
  <last_update_submitted_qc>April 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Nancy J. Brown, MD</investigator_full_name>
    <investigator_title>Hugh J. Morgan Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Bradykinin</mesh_term>
    <mesh_term>Kininogens</mesh_term>
    <mesh_term>Sacubitril and valsartan sodium hydrate drug combination</mesh_term>
    <mesh_term>Substance P</mesh_term>
    <mesh_term>Neurokinin A</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

